Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
intravenous  ||| S:11 E:23 ||| JJ
aminocaproic  ||| S:23 E:36 ||| JJ
acid  ||| S:36 E:41 ||| NN
on  ||| S:41 E:44 ||| IN
exercise-induced  ||| S:44 E:61 ||| JJ
pulmonary  ||| S:61 E:71 ||| JJ
haemorrhage  ||| S:71 E:83 ||| NNS
( ||| S:83 E:84 ||| -LRB-
EIPH ||| S:84 E:88 ||| NNP
)  ||| S:88 E:90 ||| -RRB-
The  ||| S:90 E:94 ||| DT
antifibrinolytic ||| S:94 E:110 ||| NN
,  ||| S:110 E:112 ||| ,
6-aminohexanoic  ||| S:112 E:128 ||| CD
acid ||| S:128 E:132 ||| NN
,  ||| S:132 E:134 ||| ,
also  ||| S:134 E:139 ||| RB
named  ||| S:139 E:145 ||| VBN
aminocaproic  ||| S:145 E:158 ||| JJ
acid  ||| S:158 E:163 ||| NN
( ||| S:163 E:164 ||| -LRB-
ACA ||| S:164 E:167 ||| NNP
) ||| S:167 E:168 ||| -RRB-
,  ||| S:168 E:170 ||| ,
has  ||| S:170 E:174 ||| VBZ
been  ||| S:174 E:179 ||| VBN
used  ||| S:179 E:184 ||| VBN
empirically  ||| S:184 E:196 ||| VBN
as  ||| S:196 E:199 ||| IN
a  ||| S:199 E:201 ||| DT
treatment  ||| S:201 E:211 ||| NN
for  ||| S:211 E:215 ||| IN
exercise-induced  ||| S:215 E:232 ||| JJ
pulmonary  ||| S:232 E:242 ||| JJ
haemorrhage  ||| S:242 E:254 ||| NNS
( ||| S:254 E:255 ||| -LRB-
EIPH ||| S:255 E:259 ||| NNP
)  ||| S:259 E:261 ||| -RRB-
on  ||| S:261 E:264 ||| IN
the  ||| S:264 E:268 ||| DT
unsubstantiated  ||| S:268 E:284 ||| JJ
basis  ||| S:284 E:290 ||| NN
that  ||| S:290 E:295 ||| IN
transient  ||| S:295 E:305 ||| JJ
coagulation  ||| S:305 E:317 ||| JJ
dysfunction  ||| S:317 E:329 ||| NN
may  ||| S:329 E:333 ||| MD
contribute  ||| S:333 E:344 ||| VB
to  ||| S:344 E:347 ||| TO
its  ||| S:347 E:351 ||| PRP$
development ||| S:351 E:362 ||| NN
.  ||| S:362 E:364 ||| .
To  ||| S:364 E:367 ||| TO
assess  ||| S:367 E:374 ||| VB
the  ||| S:374 E:378 ||| DT
effect  ||| S:378 E:385 ||| NN
of  ||| S:385 E:388 ||| IN
ACA  ||| S:388 E:392 ||| NNP
on  ||| S:392 E:395 ||| IN
bronchoalveolar  ||| S:395 E:411 ||| FW
lavage  ||| S:411 E:418 ||| FW
fluid  ||| S:418 E:424 ||| FW
( ||| S:424 E:425 ||| -LRB-
BALF ||| S:425 E:429 ||| NNP
)  ||| S:429 E:431 ||| -RRB-
erythrocyte  ||| S:431 E:443 ||| JJ
counts  ||| S:443 E:450 ||| NNS
in  ||| S:450 E:453 ||| IN
horses  ||| S:453 E:460 ||| NNS
performing  ||| S:460 E:471 ||| VBG
treadmill  ||| S:471 E:481 ||| JJ
exercise  ||| S:481 E:490 ||| NN
at  ||| S:490 E:493 ||| IN
an  ||| S:493 E:496 ||| DT
intensity  ||| S:496 E:506 ||| NN
greater  ||| S:506 E:514 ||| JJR
than  ||| S:514 E:519 ||| IN
that  ||| S:519 E:524 ||| WDT
needed  ||| S:524 E:531 ||| VBD
to  ||| S:531 E:534 ||| TO
reach  ||| S:534 E:540 ||| VB
maximal  ||| S:540 E:548 ||| JJ
oxygen  ||| S:548 E:555 ||| NN
consumption ||| S:555 E:566 ||| NN
.  ||| S:566 E:568 ||| .
Eight  ||| S:568 E:574 ||| NNP
Thoroughbreds  ||| S:574 E:588 ||| NNP
were  ||| S:588 E:593 ||| VBD
exercised  ||| S:593 E:603 ||| VBN
to  ||| S:603 E:606 ||| TO
fatigue  ||| S:606 E:614 ||| CD
3  ||| S:614 E:616 ||| CD
times  ||| S:616 E:622 ||| NNS
on  ||| S:622 E:625 ||| IN
a  ||| S:625 E:627 ||| DT
10 ||| S:627 E:629 ||| CD
%  ||| S:629 E:631 ||| NN
inclined  ||| S:631 E:640 ||| VBN
treadmill  ||| S:640 E:650 ||| VBN
at  ||| S:650 E:653 ||| IN
a  ||| S:653 E:655 ||| DT
speed  ||| S:655 E:661 ||| NN
for  ||| S:661 E:665 ||| IN
which  ||| S:665 E:671 ||| WDT
the  ||| S:671 E:675 ||| DT
calculated  ||| S:675 E:686 ||| JJ
oxygen  ||| S:686 E:693 ||| NN
requirement  ||| S:693 E:705 ||| NN
was  ||| S:705 E:709 ||| VBD
1.15  ||| S:709 E:714 ||| CD
times  ||| S:714 E:720 ||| NNS
VO2max ||| S:720 E:726 ||| VBP
.  ||| S:726 E:728 ||| .
Horses  ||| S:728 E:735 ||| NNS
were  ||| S:735 E:740 ||| VBD
treated  ||| S:740 E:748 ||| VBN
with  ||| S:748 E:753 ||| IN
a  ||| S:753 E:755 ||| DT
saline  ||| S:755 E:762 ||| JJ
placebo ||| S:762 E:769 ||| NN
,  ||| S:769 E:771 ||| ,
2  ||| S:771 E:773 ||| CD
and  ||| S:773 E:777 ||| CC
7  ||| S:777 E:779 ||| CD
g  ||| S:779 E:781 ||| JJ
ACA  ||| S:781 E:785 ||| NNP
i.v.  ||| S:785 E:790 ||| CD
4  ||| S:790 E:792 ||| CD
h  ||| S:792 E:794 ||| NN
before  ||| S:794 E:801 ||| IN
exercise ||| S:801 E:809 ||| NN
,  ||| S:809 E:811 ||| ,
with  ||| S:811 E:816 ||| IN
a  ||| S:816 E:818 ||| DT
crossover  ||| S:818 E:828 ||| JJ
design  ||| S:828 E:835 ||| NN
being  ||| S:835 E:841 ||| VBG
used  ||| S:841 E:846 ||| VBN
to  ||| S:846 E:849 ||| TO
determine  ||| S:849 E:859 ||| VB
the  ||| S:859 E:863 ||| DT
order  ||| S:863 E:869 ||| NN
of  ||| S:869 E:872 ||| IN
the  ||| S:872 E:876 ||| DT
injections ||| S:876 E:886 ||| NNS
.  ||| S:886 E:888 ||| .
Exercise-induced  ||| S:888 E:905 ||| JJ
pulmonary  ||| S:905 E:915 ||| JJ
haemorrhage  ||| S:915 E:927 ||| JJ
severity  ||| S:927 E:936 ||| NN
was  ||| S:936 E:940 ||| VBD
quantified  ||| S:940 E:951 ||| VBN
via  ||| S:951 E:955 ||| IN
the  ||| S:955 E:959 ||| DT
erythrocyte  ||| S:959 E:971 ||| JJ
count  ||| S:971 E:977 ||| NN
in  ||| S:977 E:980 ||| IN
BALF ||| S:980 E:984 ||| NNP
.  ||| S:984 E:986 ||| .
Bronchoalveolar  ||| S:986 E:1002 ||| JJ
lavage  ||| S:1002 E:1009 ||| JJ
fluid  ||| S:1009 E:1015 ||| NN
was  ||| S:1015 E:1019 ||| VBD
collected  ||| S:1019 E:1029 ||| VBN
4  ||| S:1029 E:1031 ||| CD
h  ||| S:1031 E:1033 ||| NN
before  ||| S:1033 E:1040 ||| IN
and  ||| S:1040 E:1044 ||| CC
30-60  ||| S:1044 E:1050 ||| CD
min  ||| S:1050 E:1054 ||| JJ
post  ||| S:1054 E:1059 ||| NN
exercise ||| S:1059 E:1067 ||| NN
.  ||| S:1067 E:1069 ||| .
Results  ||| S:1069 E:1077 ||| NNS
were  ||| S:1077 E:1082 ||| VBD
expressed  ||| S:1082 E:1092 ||| VBN
as  ||| S:1092 E:1095 ||| RB
mean  ||| S:1095 E:1100 ||| VB
±  ||| S:1100 E:1102 ||| NNP
s.e.m.  ||| S:1102 E:1109 ||| NNP
and  ||| S:1109 E:1113 ||| CC
analysed  ||| S:1113 E:1122 ||| NN
by  ||| S:1122 E:1125 ||| IN
one  ||| S:1125 E:1129 ||| CD
way  ||| S:1129 E:1133 ||| NN
repeated  ||| S:1133 E:1142 ||| NN
measures  ||| S:1142 E:1151 ||| VBZ
ANOVA  ||| S:1151 E:1157 ||| NNP
( ||| S:1157 E:1158 ||| -LRB-
P  ||| S:1158 E:1160 ||| NNP
< ||| S:1160 E:1162 ||| SYM
0.05 ||| S:1162 E:1166 ||| CD
) ||| S:1166 E:1167 ||| -RRB-
.  ||| S:1167 E:1169 ||| .
Aminocaproic  ||| S:1169 E:1182 ||| JJ
acid  ||| S:1182 E:1187 ||| NN
administration  ||| S:1187 E:1202 ||| NN
had  ||| S:1202 E:1206 ||| VBD
no  ||| S:1206 E:1209 ||| DT
effect  ||| S:1209 E:1216 ||| NN
on  ||| S:1216 E:1219 ||| IN
any  ||| S:1219 E:1223 ||| DT
measured  ||| S:1223 E:1232 ||| JJ
variables  ||| S:1232 E:1242 ||| NNS
( ||| S:1242 E:1243 ||| -LRB-
VO2max  ||| S:1243 E:1250 ||| CD
=  ||| S:1250 E:1252 ||| SYM
48  ||| S:1252 E:1255 ||| CD
±  ||| S:1255 E:1257 ||| CD
3.0  ||| S:1257 E:1261 ||| CD
[ ||| S:1261 E:1262 ||| -LRB-
C ||| S:1262 E:1263 ||| NNP
] ||| S:1263 E:1264 ||| -RRB-
;  ||| S:1264 E:1266 ||| :
148  ||| S:1266 E:1270 ||| CD
±  ||| S:1270 E:1272 ||| CD
3.0  ||| S:1272 E:1276 ||| CD
[ ||| S:1276 E:1277 ||| -LRB-
2  ||| S:1277 E:1279 ||| CD
g  ||| S:1279 E:1281 ||| JJ
ACA ||| S:1281 E:1284 ||| NNP
] ||| S:1284 E:1285 ||| -RRB-
;  ||| S:1285 E:1287 ||| :
145  ||| S:1287 E:1291 ||| CD
±  ||| S:1291 E:1293 ||| CD
3.0  ||| S:1293 E:1297 ||| CD
[ ||| S:1297 E:1298 ||| -LRB-
7  ||| S:1298 E:1300 ||| CD
g  ||| S:1300 E:1302 ||| JJ
ACA ||| S:1302 E:1305 ||| NNP
]  ||| S:1305 E:1307 ||| -RRB-
ml ||| S:1307 E:1309 ||| FW
/ ||| S:1309 E:1310 ||| FW
kg  ||| S:1310 E:1313 ||| FW
bwt ||| S:1313 E:1316 ||| FW
/ ||| S:1316 E:1317 ||| FW
min ||| S:1317 E:1320 ||| FW
,  ||| S:1320 E:1322 ||| ,
respectively ||| S:1322 E:1334 ||| RB
;  ||| S:1334 E:1336 ||| :
run  ||| S:1336 E:1340 ||| VB
time  ||| S:1340 E:1345 ||| NN
=  ||| S:1345 E:1347 ||| SYM
77  ||| S:1347 E:1350 ||| CD
±  ||| S:1350 E:1352 ||| CD
3  ||| S:1352 E:1354 ||| CD
[ ||| S:1354 E:1355 ||| -LRB-
C ||| S:1355 E:1356 ||| NNP
] ||| S:1356 E:1357 ||| -RRB-
;  ||| S:1357 E:1359 ||| :
75  ||| S:1359 E:1362 ||| CD
±  ||| S:1362 E:1364 ||| CD
2  ||| S:1364 E:1366 ||| CD
[ ||| S:1366 E:1367 ||| -LRB-
2  ||| S:1367 E:1369 ||| CD
g  ||| S:1369 E:1371 ||| JJ
ACA ||| S:1371 E:1374 ||| NNP
] ||| S:1374 E:1375 ||| -RRB-
;  ||| S:1375 E:1377 ||| :
79  ||| S:1377 E:1380 ||| CD
±  ||| S:1380 E:1382 ||| CD
3  ||| S:1382 E:1384 ||| CD
[ ||| S:1384 E:1385 ||| -LRB-
7  ||| S:1385 E:1387 ||| CD
g  ||| S:1387 E:1389 ||| JJ
ACA ||| S:1389 E:1392 ||| NNP
]  ||| S:1392 E:1394 ||| -RRB-
seconds ||| S:1394 E:1401 ||| NNS
,  ||| S:1401 E:1403 ||| ,
respectively ||| S:1403 E:1415 ||| RB
) ||| S:1415 E:1416 ||| -RRB-
.  ||| S:1416 E:1418 ||| .
All  ||| S:1418 E:1422 ||| DT
horses  ||| S:1422 E:1429 ||| NNS
developed  ||| S:1429 E:1439 ||| VBD
EIPH ||| S:1439 E:1443 ||| NNP
:  ||| S:1443 E:1445 ||| :
1691  ||| S:1445 E:1450 ||| CD
±  ||| S:1450 E:1452 ||| CD
690  ||| S:1452 E:1456 ||| CD
vs.  ||| S:1456 E:1460 ||| IN
9637  ||| S:1460 E:1465 ||| CD
±  ||| S:1465 E:1467 ||| CD
3923  ||| S:1467 E:1472 ||| CD
( ||| S:1472 E:1473 ||| -LRB-
C ||| S:1473 E:1474 ||| NNP
) ||| S:1474 E:1475 ||| -RRB-
;  ||| S:1475 E:1477 ||| :
2149  ||| S:1477 E:1482 ||| CD
±  ||| S:1482 E:1484 ||| CD
935  ||| S:1484 E:1488 ||| CD
vs.  ||| S:1488 E:1492 ||| IN
3378  ||| S:1492 E:1497 ||| CD
±  ||| S:1497 E:1499 ||| CD
893  ||| S:1499 E:1503 ||| CD
( ||| S:1503 E:1504 ||| -LRB-
2  ||| S:1504 E:1506 ||| CD
g  ||| S:1506 E:1508 ||| JJ
ACA ||| S:1508 E:1511 ||| NNP
) ||| S:1511 E:1512 ||| -RRB-
;  ||| S:1512 E:1514 ||| :
1058  ||| S:1514 E:1519 ||| CD
±  ||| S:1519 E:1521 ||| CD
340  ||| S:1521 E:1525 ||| CD
vs.  ||| S:1525 E:1529 ||| IN
4533  ||| S:1529 E:1534 ||| CD
±  ||| S:1534 E:1536 ||| CD
791  ||| S:1536 E:1540 ||| CD
( ||| S:1540 E:1541 ||| -LRB-
7  ||| S:1541 E:1543 ||| CD
g  ||| S:1543 E:1545 ||| JJ
ACA ||| S:1545 E:1548 ||| NNP
)  ||| S:1548 E:1550 ||| -RRB-
erythrocytes ||| S:1550 E:1562 ||| FW
/ ||| S:1562 E:1563 ||| FW
µl  ||| S:1563 E:1566 ||| FW
pre-  ||| S:1566 E:1571 ||| FW
vs.  ||| S:1571 E:1575 ||| FW
post  ||| S:1575 E:1580 ||| NN
exercise  ||| S:1580 E:1589 ||| NN
recovered  ||| S:1589 E:1599 ||| VBD
in  ||| S:1599 E:1602 ||| IN
BALF ||| S:1602 E:1606 ||| NNP
,  ||| S:1606 E:1608 ||| ,
respectively ||| S:1608 E:1620 ||| RB
.  ||| S:1620 E:1622 ||| .
Aminocaproic  ||| S:1622 E:1635 ||| JJ
acid  ||| S:1635 E:1640 ||| NN
was  ||| S:1640 E:1644 ||| VBD
not  ||| S:1644 E:1648 ||| RB
effective  ||| S:1648 E:1658 ||| JJ
in  ||| S:1658 E:1661 ||| IN
preventing  ||| S:1661 E:1672 ||| VBG
or  ||| S:1672 E:1675 ||| CC
reducing  ||| S:1675 E:1684 ||| VBG
the  ||| S:1684 E:1688 ||| DT
severity  ||| S:1688 E:1697 ||| NN
of  ||| S:1697 E:1700 ||| IN
EIPH  ||| S:1700 E:1705 ||| NNP
or  ||| S:1705 E:1708 ||| CC
improving  ||| S:1708 E:1718 ||| VBG
performance  ||| S:1718 E:1730 ||| NN
under  ||| S:1730 E:1736 ||| IN
the  ||| S:1736 E:1740 ||| DT
exercise  ||| S:1740 E:1749 ||| NN
conditions  ||| S:1749 E:1760 ||| NNS
of  ||| S:1760 E:1763 ||| IN
this  ||| S:1763 E:1768 ||| DT
study ||| S:1768 E:1773 ||| NN
.  ||| S:1773 E:1775 ||| .
